Nivolumab With Ipilimumab Have an Added Benefit in Mesothelioma

A pure antibody combination is approved as first-line therapy for unresectable malignant pleural mesothelioma for the first time. Added benefit is not yet proven for patients with epithelioid histology.

Related Keywords

Germany ,German , ,Efficiency In Health Care Iqwi ,German Institute For Quality ,German Institute ,Health Care ,Mesothelioma ,Nivolumab Ipilimumab ,Drug Combination ,Malignancy ,Leural Tumors ,Pithelioid Tumors ,